The prevalence and prevention of nasopharyngeal carcinoma in China

Su-Mei Cao¹², Malcolm J. Simons³⁴, and Chao-Nan Qian¹⁵⁶

Abstract

Nasopharyngeal carcinoma (NPC) has remarkable epidemiological features, including regional, racial, and familial aggregations. The aim of this review is to describe the epidemiological characteristics of NPC and to propose possible causes for the high incidence patterns in southern China. Since the etiology of NPC is not completely understood, approaches to primary prevention of NPC remain under consideration. This situation highlights the need to conduct secondary prevention, including improving rates of early detection, early diagnosis, and early treatment in NPC patients. Since the 1970’s, high-risk populations in southern China have been screened extensively for early detection of NPC using anti–Epstein-Barr virus (EBV) serum biomarkers. This review summarizes several large screening studies that have been conducted in the high-incidence areas of China. Screening markers, high-risk age range for screening, time intervals for blood re-examination, and the effectiveness of these screening studies will be discussed. Conduction of prospective randomized controlled screening trials in southern China can be expected to maximize the cost-effectiveness of early NPC detection screening.

Key words Nasopharyngeal carcinoma, epidemiology, screening

Descriptive Epidemiology

The epidemiology of nasopharyngeal carcinoma (NPC) is characterized by its unique geographic distribution. Southern China has one of the highest incidence rates of NPC in the world. Decades of epidemiological studies have shown that NPC has unique prevalence features, including regional, racial and familial aggregation.

According to the global registry of cancer incidence, NPC ranked 11th among all malignancies in China in 2008, with an incidence rate of 2.8/100 000 person-years in men and 1.9/100 000 person-years in women. This reflects the fact that the incidence and mortality rate of NPC vary greatly in different areas in China (Table 1) [1,2]. The trend is towards a lower incidence rate in North and West China and a higher rate in South and East China. Five provinces, including Guangdong, Hainan, Guangxi, Hunan, and Fujian, have higher incidence rates of NPC. Highest rates are noted among the Cantonese who inhabit the cities and counties in Pearl River Delta and West Pearl River Valley, of which Zhaoqing area, Zhangshan City, and Guangzhou City form a core high-incidence zone [3]. Sihui City in Zhaoqing area has the highest overall incidence, with a rate of 27.2/100 000 person-years in men and 11.3/100 000 person-years in women in the year 2003 [4]. In Northern China, no county has an annual mortality rate higher than 3/100 000 persons. Since no complete NPC incidence data in China can be obtained, the authoritative mortality data in Investigation of Cancer Mortality in China [5], published in 1979, was used as a reference to describe the overall distribution of NPC (Figure 1).
There is a common feature across populations demonstrating that the incidence rate of NPC in men is higher than in women, with a ratio of 2–3 to 1\(^\text{[1]}\) independent of the area. On the other hand, NPC has different age-specific rate distributions in areas with high or low incidence rates. For most low-incidence areas, NPC incidence rises monotonically with age \[^{[6]}\]. In contrast, NPC incidence among high-risk Cantonese of both sexes increases with age until it peaks between 40 and 59 years, after which it shows a significant
This may be explained by early life exposure to carcinogenic agents. In some high-incidence areas in the world, such as Hong Kong\textsuperscript{[9]}, Taiwan\textsuperscript{[11]} and Singapore\textsuperscript{[12]}, the time trend incidence of NPC has declined significantly. A decreasing time trend was also observed in the Shanghai female population, with moderate risk during the 23 years from 1972–1974 to 1993–1994\textsuperscript{[9]}. Among the Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, the incidence also significantly decreased, and the overall decline in incidence was primarily due to a decline in the rate of type I tumors\textsuperscript{[14]}. However, in traditional high-incidence areas in southern China, such as Sihui City in Guangdong province and Cangwu County in Guangxi province, the NPC incidence rate has remained stable for the last 20 years\textsuperscript{[2]} (Table 2). Moreover, some areas, such as Zhongshan City, Guangdong province, show a trend towards increasing NPC incidence, with a world standardized incidence rate of 14.02/100 000 person-years in 1970 and 17.02/100 000 person-years in 1999, corresponding to an increase of 21.40\% in the last 30 years\textsuperscript{[15]}.

The differences in time trends of NPC in these areas above mentioned may be related to changes in risk factor exposure in the corresponding populations. Although there is no strong supportive evidence, it may be attributable to the changing lifestyle among local residents from traditional Chinese to Western diets, followed by rapid economic growth and development in these corresponding areas. Changes in smoking habit, pickled food intake, and immigration may have great influences on incidence in the Hong Kong, Singapore, and Taiwan populations\textsuperscript{[2,10–12]}. Other investigators found that in the United States, the decline in NPC incidence was mainly due to a decrease in keratinizing squamous cell carcinoma (WHO grade I), while the incidence of non-keratinizing carcinoma (WHO grades II and III) remained stable. Epidemiological studies found that smoking was the major factor causing keratinizing squamous cell carcinoma but had little to do with the incidence of non-keratinizing squamous cell carcinoma\textsuperscript{[16]}. Thus, the decline of population smoking rate in these areas could at least partly, if not largely, explain the decline of NPC incidence.

In the past thirty years, in high-incidence areas in southern China such as Guangdong and Guangxi provinces, the economy has developed rapidly and people’s diets and lifestyles as well as other aspects have greatly changed. Nevertheless, the NPC incidence rate has not decreased. More than 90\% of NPC in these areas is non-keratinizing carcinoma, indicating that risk factors for non-keratinizing squamous cell carcinoma have remained stable among people in southern China. If the environmental etiological factors exist, their impact on NPC incidence may fall behind economic development and lifestyle change for several decades. The real economic development of China occurred in the early 1990’s, so NPC incidence may have begun to decrease in southern China only in the subsequent 10–20 years.

NPC is a cancer with obvious familial aggregation. High-incidence families of NPC have been reported in both high-incidence\textsuperscript{[17–19]} and low-incidence areas\textsuperscript{[20–22]}. Moreover, the proportion of cancer patients with a family history is higher in high-incidence areas than in low-incidence areas. For example, the proportion of NPC patients with a family history is 7.2\% and 5.9\% in the high-incidence areas Hong Kong\textsuperscript{[23]} and Guangzhou\textsuperscript{[24]}, respectively, whereas in middle-incidence areas such as Shanghai, it is 1.85\%\textsuperscript{[25]}. In cancer families, NPC occurs mainly in the first-degree relatives of the proband, and the incidence in first-degree relatives of NPC patients is 4–10 times that of the control group\textsuperscript{[23,26]}. A complex segregation analysis in high-incidence families with NPC of preponderantly non-keratinizing type in southern China found no evidence for the role of a major gene, but rather that this histopathological type of NPC is a cancer with a multi-factorial mode of inheritance\textsuperscript{[27]}. No matter where people in high-incidence areas of NPC in southern China migrate, including places like the United States, Australia, and Japan, the incidence of NPC is much higher in these people than in the local residents; however, the incidence of NPC in the second and third

| Period       | Age-standard–incidence rate | Cangwu City | Sihui City |
|--------------|----------------------------|-------------|------------|
|              | Males                      | Females     | Males      | Females    |
| 1983–1987    | 17.81                      | 7.44        | 28.68      | 14.79      |
| 1988–1992    | 18.68                      | 6.91        | 28.65      | 13.35      |
| 1993–1997    | 19.43                      | 7.23        | 28.03      | 11.81      |
| 1998–2002    | 19.76                      | 7.33        | 30.94      | 13.00      |

Data are values per 100 000 person-years.
NPC in China have been mainly concentrated in areas with a mortality more than 6/100 000 (standard rate by Chinese population) such as Guangdong and Guangxi provinces.

EBV-associated antibodies have a high sensitivity and specificity in NPC and can, therefore, be used for NPC diagnosis and as screening predictors. For example, IgA antibodies against EBV capsid antigen (VCA/IgA) provide a sensitivity and a specificity of up to 90% in the diagnosis of NPC, and multiple indicators have a better result. Recent evaluation of anti-EBV biomarkers of VCA/IgA and IgA antibodies with ELISA-based EBV nuclear antigen 1 (EBNA1/IgA) confirmed the value of the combination diagnostic test employed in our previous retrospective performance studies, with a sensitivity of 95.29% and a specificity of 94.07% (unpublished data). NPC has a long pre-clinical phase, with an average time of 38 months from positive VCA/IgA antibody of EBV to the detection of NPC. Furthermore, the examination of EBV-related antibodies is simple and cheap and can be conducted in many primary health care units. The patients with early stage (stages I and II) NPC have a satisfactory treatment result, with a 5-year survival rate of up to 94%, which is significantly different from that of patients diagnosed with late stage (stages III and IV) NPC, with a 5-year survival rate lower than 80%.

The incidence of NPC begins to significantly increase after 30 years old, reaches a peak between 50 and 59 years old, and then begins to decline after 60 years old. Thus, people ranging in age from 30 to 59 generally comprise a suitable population for screening in high-incidence areas. The main NPC screening method is detection of EBV antibody and concurrent head and neck physical examination for the healthy residents ranging in age from 30 to 59 in high-risk areas. Commonly used EBV antibody indicators include VCA/IgA and EA/IgA examined by immune enzymatic methods. For subjects with a positive result of EBV antibody detection and head and neck abnormality, nasopharyngeal fiber endoscopy is performed and pathological biopsy is undertaken for confirmation of diagnosis where indicated. In recent years, the effects on the diagnosis of NPC by a variety of EBV-related indicators were comprehensively evaluated, and it has emerged that the combined detection of VCA/IgA and EBNA1/IgA by ELISA is superior to the traditional detection of VCA/IgA and EA/IgA by the immune enzymatic method. These new indicators have been used in a cluster randomized controlled population screening study in high-incidence areas of NPC in Guangdong province (http://clinicaltrials.gov/ct2/show/NCT00941538?term=nasopharyngeal+carcinoma&rank=5). An NPC screening trial was launched in 2008 in two high-risk areas in southern China, Sihui and Zhongshan. In the initial round of the trial, which was conducted...
between May 2008 and February 2010, about 60,000 subjects were recruited from randomly selected towns and communes by the cluster sampling method. Subjects who voluntarily attended the screening study were requested to donate a blood sample for serological test. All 37 NPC patients identified until now, 75.7% (28/37) of whom had early stage tumors, were included in the serologically-defined high-risk population.

Since EBV antibody levels are dynamic, the current frequency of NPC screening is usually adapted to the individual. As EBV antibody levels change, the cancer screening interval is periodically adjusted by reclassifying subjects according to their altered risk status in the follow-up period[46,36].

The definitions of risk for NPC screening and the corresponding screening intervals are shown in Table 3.

In China, Zeng et al. [41] first established the simple immune enzymatic method, which could examined the EBV antibody VCA/IgA in normal people, in the laboratory in 1976. In 1978, the first prospective prevention and treatment study site of NPC was founded in Wuzhou, Guangxi province, and 12,934 people were screened for NPC using EBV antibodies (VCA/IgA and EA/IgA) as the main screening indicators[42]. In this study, 13 patients with NPC were screened out, 9 in stage I and 4 in stage II[42]. Since then, several large-scale NPC screenings have been carried out in Guangxi, Guangdong and other places, and the screening results show that the early diagnosis rates of NPC in the screened population were all more than 80%[35,36,43-48].

Although NPC screening has been widely conducted in southern China, its exact effect is still difficult to determine. The main problems in the ongoing screening studies include the following: (1) A control group has not been included in some screening studies, or outpatients are being used as “controls” in some studies. These “controls” are unsuitable as comparison subjects for protocol evaluation; (2) Mortality needs to be included along with clinical stages and recent results of detected patients as indicators for evaluating the effect of screening; and (3) There is a lack of a cost-effective evaluation.

Thus, in order to accurately evaluate the effect of screening, randomized controlled screening studies should be carried out in high-incidence areas of NPC in southern China. Long-term follow-up should be performed to record mortality in both subject screening and control groups, and health economic evaluation should also be conducted.

Received: 2010-07-26; revised: 2011-01-10; accepted: 2011-01-11.

### Table 3. The definitions of different risk group population for NPC screening and the corresponding screening intervals

| Group               | Definition                                                                 | Screening interval       |
|---------------------|---------------------------------------------------------------------------|--------------------------|
| High-risk population| a) Subjects with an immunoenzymic assay titer of VCA/IgA ≥ 1:80; b) Subjects in whom both titers of VCA/IgA and EA/IgA are ≥ 1:5; and c) Subjects in whom either VCA/IgA and/or EA/IgA titer rises monotonically in the screening periods. | Every 6 months to 1 year |
|                     | The population with a positive result but that do not meet the high-risk criteria | Every 2 to 3 years       |
| Negative population | Subjects with negative result of EBV antibody detection                   | Every 5 years            |

### References

[1] Jia WH, Huang QH, Liao J, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Shui and Cangwu counties in southern China [J]. BMC Cancer, 2006;6:178–186.
[2] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005;55(2):74–108.
[3] Min HQ. The time trends of nasopharyngeal carcinoma: incidence rate and mortality for 20 years [M]. Min HQ. Study of nasopharyngeal carcinoma. Guangzhou: Science and Technology Press, 1998:6–12. [in Chinese]
[4] Zhang SW, Chen WQ, Kong LZ, et al. An annual report: cancer incidence in 35 cancer registries in China, 2003 [J]. Bull of Chin Cancer, 2007;16(7):484–506. [in Chinese]
[5] Cancer Research Office of Ministry of Health. Investigation of cancer mortality in China [M]. Beijing: People’s Medical Publishing House, 1979:224–249. [in Chinese]
[6] Burt RD, Vaughan TL, McKnight B. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States [J]. Int J Cancer, 1992;52(4):549–556.
[7] Lee JT, Ko CY. Has survival improved for nasopharyngeal carcinoma in the United States? [J]. Otolaryngol Head Neck Surg, 2005;132(2):303–308.
[8] Levine PH, Connelly RR, Easton JM. Demographic patterns for nasopharyngeal carcinoma in the United States [J]. Int J Cancer, 1980;26(6):741–748.
[9] Zong YS, Zhang RF, He SY, et al. Histopathologic types and incidence of malignant nasopharyngeal tumors in Zhongshan County [J]. Chin Med J (Engl), 1983;96(7):511–516.
Su-Mei Cao et al.  
Epidemiology of NPC in China

[10] Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980–1999): an encouraging reduction in both incidence and mortality [J]. Int J Cancer, 2003, 103(5):680–685.

[11] Hsu C, Shen YC, Cheng CC, et al. Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis [J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(5):866–869.

[12] Luo J, Chia KS, Chia SE, et al. Secular trends of nasopharyngeal carcinoma incidence in Singapore, Hong Kong and Los Angeles Chinese populations, 1973–1997 [J]. Eur J Epidemiol, 2007, 22(8):513–521.

[13] Jin F, Devesa SS, Chow WH, et al. Cancer incidence trends in urban Shanghai, 1972–1994: an update [J]. Int J Cancer, 1999, 82(4):435–440.

[14] Sun LM, Epplin M, Li CI, et al. Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992–2002 [J]. Am J Epidemiol, 2005, 162(12):1174 – 1178.

[15] Wei KR, Liu Q, Wang DK, et al. Incidence trend and prediction of nasopharyngeal carcinoma in Zhongshan during 1970–1999 [J]. Chin J Cancer, 2001, 20(10):1065–1068. [in Chinese]

[16] Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type [J]. Cancer Epidemiol Biomarkers Prev, 1996, 5(8):587–590.

[17] Jung PF. Familial tendency of nasopharyngeal carcinoma: a report of cases [J]. Pac Med Surg, 1965, 73:242–243.

[18] Ko JY, Sheen TS, Hsu MM, et al. Familial clustering of nasopharyngeal carcinoma [J]. Otolaryngol Head Neck Surg, 1998, 118(5):736–737.

[19] Zhang F, Zhang J. Clinical hereditary characteristics in nasopharyngeal carcinoma through Ye-Liang’s family cluster [J]. Chin Med J (Engl), 1999, 112(2):185–187.

[20] Bell RB, Magruda TA. Nasopharyngeal carcinoma in Caucasian siblings: report of two cases [J]. J Tenn Med Assoc, 1970, 63(9):753–754.

[21] Nevo S, Meyer W, Altman M. Carcinoma of nasopharynx in twins [J]. Cancer, 1971, 28(3):807–809.

[22] Snow JB, Jr. Carcinoma of the nasopharynx in children [J]. Ann Otol Rhinol Laryngol, 1975, 84(6):817–826.

[23] Yu MC, Ho JH, Lui SH, et al. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong [J]. Cancer Res, 1986, 46(2):956–961.

[24] Yu MC, Garabrant DH, Huang TB, et al. Occupational and other non-dietary risk factors for nasopharyngeal carcinoma in Guangzhou, China [J]. Int J Cancer, 1990, 45(6):1033–1039.

[25] Yuan JM, Wang XL, Xiang YB, et al. Non-dietary risk factors for nasopharyngeal carcinoma in Shanghai, China [J]. Int J Cancer, 2000, 85(3):364–369.

[26] Chen CJ, Liang KY, Chang YS, et al. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency [J]. Anticancer Res, 1990, 10(28):547–553.

[27] Jia WH, Collins A, Zeng YX, et al. Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China) [J]. Eur J Hum Genet, 2005, 13(2):248–252.

[28] McCredie M, Williams S, Coates M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975–1995 [J]. Br J Cancer, 1999, 79(7–8):1277–1282.

[29] Warnakulasuriya KA, Johnson NW, Linklater KM, et al. Cancer of mouth, pharynx and nasopharynx in Asian and Chinese immigrants resident in Thames regions [J]. Oral Oncol, 1999, 35(5):471–476.

[30] Buell P. Race and place in the etiology of nasopharyngeal cancer: a study based on California death certificates [J]. Int J Cancer, 1973, 11(2):268–272.

[31] Li CC, Yu MC, Henderson BE. Some epidemiologic observations of nasopharyngeal carcinoma in Guangdong, People’s Republic of China [J]. Natl Cancer Inst Monogr, 1984, 59:69–92.

[32] Lee HP, Duffy SW, Day NE, et al. Recent trends in cancer incidence among Singapore Chinese [J]. Int J Cancer, 1988, 42(2):159–166.

[33] Shannagaratnam K. Nasopharyngeal carcinoma: epidemiology, histopathology and aetiology [J]. Ann Acad Med Singapore, 1980, 9(3):289–295.

[34] Wee JT, Ha TC, Loong SL. Is nasopharyngeal cancer really a “Cantonese cancer”? [J]. Chin J Cancer, 2010, 29(6):517–521.

[35] Huang TB, Wang HM, Li JL, et al. Screening program for nasopharyngeal carcinoma (NPC) — early detection for NPC [J]. Chin J Cancer, 1997, 16(4):245–247. [in Chinese]

[36] Jiang SQ, Liu Q. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma [J]. Ai Zheng, 2009, 28(2):177–180.

[37] Ji MF, Wang DK, Yu YL, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma [J]. Br J Cancer, 2007, 96(4):623–630.

[38] Ji MF, Yu YL, Cheng WM, et al. Nasopharyngeal carcinoma: early detection by serological screening and clinical examination [J]. Chin J Cancer, 2011, 30(2):120–123.

[39] Mao YP, Li WF, Chen L, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma [J]. Ai Zheng, 2009, 28(10):1022–1028.

[40] Cao SM. Early detection and early diagnosis for nasopharyngeal carcinoma [M]. Hong MH, Guo X. Nasopharyngeal carcinoma. Beijing: China Medical Science and Technology Press, 2003:80–91. [in Chinese]

[41] Zeng Y, Li K. Virus and Oncology [M]. Zhang TZ, Xu GW, eds. Oncology. Tianjin: Tianjin Science and Technology Press, 1996: 88—105. [in Chinese]

[42] Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China [J]. Int J Cancer, 1982, 29(2):139–141.

[43] Zeng Y, Zhong JM, Li LY, et al. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China [J]. Intervirology, 1983, 20(4):190–194.

[44] Deng H, Lei YM, Tan BF, et al. Serologic mass survey on 362 247 persons for nasopharyngeal carcinoma (NPC) in south China [J]. Zhongguo Zhiou Zhi L, 1995, 17(Suppl):173. [in Chinese]

[45] Deng H, Lei YM. Serologic mass survey for nasopharyngeal carcinoma (NPC) in Wuzhou, Liuzhou and Beihai cities [J]. Guangxi Yi Xue, 1995, 17(2):93–95. [in Chinese]